CAS: 841290-80-0; 6-[5-Fluoro-2-(3,4,5-Trimethoxyphenylamino)Pyrimidin-4-Ylamino]-2,2-Dimethyl-4H-Pyrido[3,2-B][1,4]Oxazin-3-One

该化合物是一种合成化合物,属于苯氧基衍生物的类别.该物质具有复杂的分子结构,具有多种功能组的特点,包括氟丙酰胺和三甲基苯基胺,有助于其潜在的生物活动.二甲基组和氧化氮环的存在增强了其稳定性和溶解性.该化合物的药效特性已得到调查,特别是在癌症研究方面,因为它可能对肿瘤生长中涉及的特定酶或路径产生抑制性影响.其独特的结构特征表明,它与生物目标可能发生相互作用,从而成为对医学化学进行进一步研究的候选对象.然而,有关其功效,安全性和治疗作用的机理机制是其基本理解机制.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

REACH注册ECHA物质C&L通报REACH预注册

上下游产品

4-(2,2-dimethyl-4-[(di-tert-butyl-phosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamineN4-(2,2-dimethyl-4-[(di-tert-butyl-phosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine 6-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one 3,4,5-Trimethoxyaniline4-(2,2-dimethyl-4-[(di-tert-butyl-phosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamineN4-(2,2-dimethyl-4-[(di-tert-butyl-phosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine 31H42FN6O9PC31H42FN6O9P 31H42FN6O9PC31H42FN6O9P 2-chlor°Carbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamineN2-chlor°Carbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine

合成工艺路线路线简述

  • 575484-83-2 + 24313-88-0 = 841290-80-0
    反应条件:1.1 Reagents: Trifluoroacetic Acid Solvents: Methanol; Overnight,100 °C
    标题:Design,Synthesis Of Diaminopyrimidine Inhibitors Targeting Ige- And Igg-Mediated Activation Of Fc Receptor Signaling
    作者:Argade,Ankush; Bhamidipati,Somasekhar; Li,Hui; Sylvain,Catherine; Clough,Jeffrey; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2015 卷标:25(10) 页码:2122-2128]

    575484-83-2 + 24313-88-0 = 841290-80-0 + 1294007-59-2 + 946572-80-1
    反应条件:1.1 Solvents: N-Methyl-2-Pyrrolidone,Water; Rt -> 120 °C; 10 H,120 °C; 120 °C -> 65 °C1.2 Reagents: Sodium Hydroxide Solvents: Water; Ph 8.5,65 °C; 65 °C -> 20 °C; 6 H,20 °C
    标题:Real-Time Monitoring And Control Of Critical Process Impurities During The Manufacture Of Fostamatinib Disodium
    作者:Hart,Richard; Herring,Adam; Howell,Gareth P.; Mckeever-Abbas,Ben; Pedge,Nicholas; Et Al
    参考文献:Organic Process Research & Development 日期:2015 卷标:19(4) 页码:537-542
📜在 Phosphatase From Bovine Intestinal Mucosa,Magnesium Chloride体系中,化学反应生成 6-[[5-氟-2-[(3,4,5-三甲氧基苯基)氨基]-4-嘧啶基]氨基]-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-噁嗪-3(4H)-酮
参考文献:Metabolism Of Fostamatinib,The Oral Methylene Phosphate Prodrug Of The Spleen Tyrosine Kinase Inhibitor R406 In Humans: Contribution Of Hepatic And Gut Bacterial Processes To The Overall Biotransformation
标题:Metabolism Of Fostamatinib,The Oral Methylene Phosphate Prodrug Of The Spleen Tyrosine Kinase Inhibitor R406 In Humans: Contribution Of Hepatic And Gut Bacterial Processes To The Overall Biotransformation
摘要:化反应.
DOI:10.1124/dmd.110.032151

海关参考信息

专利信息


专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-8299242-B2
优先权日:2009-07-02
标 题 :Synthesis of 2,4-pyrimidinediamines

专利号:US-8481724-B2
优先权日:2009-07-02
标题:Synthesis of 2,4-pyrimidinediamines

专利号:CN-102482305-B
优先权日:2009-07-02
标题 :Synthesis of N4- (2, 2-dimethyl-4- [ (dihydrophosphonooxy) methyl ] -3-oxo-5-pyrido [1,4] oxazin-6-yl) -5-fluoro-N2- (3,4, 5-trimethoxyphenyl) -2, 4-pyrimidinediamine disodium salt

专利号:WO-2011002999-A1
优先权日:2009-07-02
标 题 :Synthesis of n4- (2, 2-dimethyl-4- [ (dihydrogen phosphonoxy ] -3-oxo-5-pyrido [1, 4] oxazin-6-yl)-5-fluoro-n2- (3, 4, 5,-trimethoxyphenyl) -2, 4- pyrimidinediamine disodium salt

专利号:US-2013274499-A1
优先权日:2009-07-02
标题 :Synthesis of 2,4-Pyrimidinediamines

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Assefi M, Lewandrowski KU, Lorio M, Fiorelli RKA; Brazilian Society For Thoracic Surgery—Sociedade Brasileira de Cirurgia Torácica (SBCT); Landgraeber S, Sharafshah A. Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis. J Pers Med. 2023 Oct 29;13(11):1550. doi: 10.3390/jpm13111550.
2: Ezzeldin E, Iqbal M, Asiri YA, Sayed AYA, Alsalahi R. Eco-Friendly UPLC-MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats. Molecules. 2021 Jul 31;26(15):4663. doi: 10.3390/molecules26154663.
3: Newland A, McDonald V. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. Immunotherapy. 2020 Dec;12(18):1325-1340. doi: 10.2217/imt-2020-0215. Epub 2020 Oct 6. 127(4):449-57. doi: 10.1182/blood-2015-07-660969. Epub 2015 Oct 21. 126(16):1902-10. doi: 10.1182/blood-2015-04-640805. Epub 2015 Jul 20. 30(1):67-99.

合成参考文献


摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2018)
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知